

Augmentation of the antimicrobial activities of guinea pig cathelicidin CAP11-derived peptides by amino acid substitutions

DAIJU OKUDA¹, SHIN YOMOGIDA¹, KYOKO KUWAHARA-ARAI²,
KEIICHI HITAMATSU², HIROSHI TAMURA³ and ISAO NAGAOKA¹

Departments of ¹Host Defense and Biochemical Research; ²Bacteriology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421; ³Seikagaku Biobusiness Corporation, 39 Kanda Higashimatsushita-cho, Chiyoda-ku, Tokyo 101-0042, Japan

Received November 19, 2008; Accepted January 15, 2009

DOI: 10.3892/ijmm_00000157

Abstract. Mammalian myeloid and epithelial cells express various peptide antibiotics (such as defensin and cathelicidin) that contribute to the innate host defense against invading microorganisms. Among these, guinea pig cathelicidin CAP11 (G¹-I⁴³) possesses potent antibacterial activities against Gram-positive and -negative bacteria, and also lipopolysaccharide-neutralizing activity. We previously revealed that the active region with antibacterial activity is localized at G¹ to R¹⁸ of CAP11. In this study, to develop peptide derivatives with enhanced antimicrobial actions, we utilized the amphipathic 18-mer peptide (G¹-R¹⁸) as a template. Antimicrobial activities of the peptides were assessed by alamarBlue assay (*Escherichia coli*, *Staphylococcus aureus* and *Candida albicans*) and colony formation assay (*Porphyromonas gingivalis*). Furthermore, the membrane-permeabilization activities were determined by using *E. coli* ML-35p as a target. By substituting K⁵, T⁹, R¹⁰, R¹², and G¹⁷ with five L residues, the hydrophobicity of the peptide (1-18m1) was increased, and by substituting G¹, and Q¹⁴ with K and R residues, respectively, the hydrophilicity (positive charge) of the peptide (1-18m2) was enhanced. Among the peptides, 1-18m2 exhibits the most potent antimicrobial and membrane-permeabilizing activities against the microorganisms examined. Thus, the antimicrobial activities of the amphipathic CAP11-derived 18-mer peptide can be augmented by modifying its hydrophobicity and hydrophilicity (positive charge), and 1-18m2 is the most potent among the peptide derivatives with therapeutic potential for Gram-positive and -negative bacterial, and fungal infections.


Introduction

Peptide antibiotics exhibit potent antimicrobial activities against both Gram-positive and -negative bacteria, fungi and viruses, and they form one group of effector components in the innate host defense system (1,2). The peptide-based defense in mammals against invading microbes relies on the two evolutionally distinct groups of antimicrobial peptides, defensins and cathelicidins, which were identified in several epithelial tissues and in the granules of phagocytes (3-9). Defensins contain conserved six cysteine residues in their sequences and exhibit characteristic β -sheet structures stabilized by three intramolecular disulfide bonds (6-8). In contrast, cathelicidins are characterized by the highly conserved cathelin-like prosequences and variable carboxyl-terminal sequences that correspond to the mature antibacterial peptides (3-5,9). About 30 cathelicidin members were identified in various mammalian species. Some are α -helical, and others are proline/arginine-rich, showing a polyproline-type structure (e.g., porcine PR39 and batenecins), whereas porcine protegrins form a β -sheet structure (3,9,10). We have characterized two α -helical cathelicidins, CAP18 (cationic antibacterial protein of 18 kDa) and CAP11 (cationic antibacterial polypeptides of 11 kDa) isolated from human and guinea pig neutrophils, respectively (11-13). CAP18 is a precursor of cathelicidin and its carboxy-terminal antibacterial peptide (hCAP18/LL-37) is cleaved from its precursor (3,9,10,14). CAP11 is also a carboxy-terminal antibacterial peptide, and has a unique homodimeric structure, in which the two identical 43-amino acid peptides are bridged by a disulfide bond (12,13).

Among antibacterial peptides, defensins completely lose their antibacterial activities in the extracellular milieu containing a physiological concentration of NaCl (150 mM) and serum (6,15). In contrast, cathelicidins, such as hCAP18/LL-37 and CAP11, exhibit antibacterial activities against Gram-negative and -positive bacteria under these conditions (15,16). Furthermore, CAP11 exhibits 10-fold more potent antibacterial activities against *Escherichia coli* and *Staphylococcus aureus* than LL-37 (15). Thus, CAP11 and its related derivatives are attractive candidates for therapeutic agents for bacterial infections (11,15-18).

Correspondence to: Dr Isao Nagaoka, Department of Host Defense and Biochemical Research, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
E-mail: nagaokai@juntendo.ac.jp

Key words: guinea pig, cathelicidin, antimicrobial host defense peptide



Reagents. Mueller Hinton broth was purchased from Difco Laboratories (Detroit, MI), heart infusion broth from Nissui

 SPANDIDOS Publications Co., Ltd. (Tokyo, Japan), Sabouraud dextrose

1 Becton Dickinson and Company (Sparks, MD), Brucella HK agar from Kyokuto Pharmaceutical Industrial Co., Ltd. (Tokyo, Japan), defibrinized sheep blood was purchased from Japan Ram Co., Ltd. (Hiroshima, Japan), hemin chloride from MP Biomedicals (Aurora, OH), PADAC (7-(thienyl-2-acetamido)-3-[2-(4-N,N-dimethyl-amino phenylazo)-pyridinium methyl]-3-cephem-4-carboxylic acid) from Calbiochem-Novabiochem (La Jolla, CA), o-nitrophenyl- β -D-galactopyranoside (ONPG) from Sigma Chemical Co. (St. Louis, MO), alamarBlue was purchased from Biosource International, Inc. (Camarillo, CA).

Synthesis and isolation of CAP11-derived peptides. A 43-mer peptide of CAP11 (G¹-I⁴³; G¹LRKKFRKTRKRIQKLGRKIGKTGRKVKAWREYQGIPYPCR^{I43}) and CAP11-derived 18-mer peptides (G¹-R¹⁸, G¹LRKKFRKTRKRIQKLGR¹⁸; 1-18m1, G¹LRKLFRKLLKLIQKLLR¹⁸ and 1-18m2, K¹LRKLFRKLLKLIQKLLR¹⁸) were synthesized by the solid-phase method on a peptide synthesizer (model PSSM-8, Shimadzu, Kyoto, Japan) by fluorenylmethoxycarbonyl (Fmoc) chemistry [underlines indicate the amino acid substitutions introduced into the original 18-mer peptide G¹-R¹⁸ to increase the hydrophobicity and hydrophilicity (positive charge) of the peptides]. The peptides were eluted from the resin and purified to homogeneity by reversed-phase high-performance liquid chromatography on a Cosmosil 5C18 column (Nacalai Tesque, Kyoto, Japan) using a 0 to 70% acetonitrile gradient in 0.1% trifluoroacetic acid. The molecular masses of the synthesized peptides were confirmed on a mass spectrometer (model TSQ 700; Thermo Quest Finnigan, Manchester, UK). G¹-I⁴³ peptides were always freshly dissolved in 0.01% HCl and used, to avoid auto-dimerization.

Assay for the antimicrobial activities. To determine the antimicrobial activities of peptides, alamarBlue was used as a metabolic indicator. As a consequence of bacterial growth, the color of an oxidation-reduction indicator alamarBlue changes from blue to pink. It was confirmed that the classical colony formation and the alamarBlue assay using a redox indicator are comparable to evaluate the bacterial viability; the results of two methods significantly correlate, and the bacterial concentrations determined by the two assays show agreement (23-25). In fact, we previously confirmed that CAP11 completely killed *E. coli* at 189 nM (1 μ g/ml) but hardly affected the bacterial growth at 18.9 nM (0.1 μ g/ml), based on the classical colony formation and alamarBlue assay (22). Thus, we evaluate the antibacterial activities of CAP11 and its derived-peptide by using alamarBlue as a metabolic indicator.

As target organisms, *E. coli*, *S. aureus* and *C. albicans* were utilized. *E. coli* (NIHJ JC-2), methicillin-sensitive *S. aureus* (MSSA) (NIHJ JC-1) and methicillin-resistant *S. aureus* (MRSA) (LR5P1-IPM8-1, a highly resistant isolate derived from N315) were supplied by Professor Keiichi Hiramatsu (Department of Bacteriology, Juntendo University, School of Medicine); *C. albicans* (CA53133) by Professor Masataro Hiruma (Department of Dermatology, Juntendo University, School of Medicine). *E. coli* and *S. aureus* were cultured in Mueller Hinton broth at 37°C for 14 h with shaking. Cells were

centrifuged, washed twice with RPMI-1640 medium without phenol red and diluted in the same medium. Bacteria were incubated in the dark at 37°C for 4 to 6 h at indicated concentrations (1x10⁷ CFU/ml, *E. coli*; 5x10⁶ CFU/ml, *S. aureus*) in RPMI-1640 medium containing 20 μ l alamarBlue in the absence or presence of antibacterial peptides dissolved in 0.01% HCl in a total volume of 200 μ l in a 96-well microplate. *C. albicans* was cultured on Sabouraud dextrose agar plates at 35°C for 14 h, and then the colonies were suspended in RPMI-1640-medium at 2.5x10⁶ CFU/ml. The cells (*C. albicans*) were incubated in the presence of alamarBlue without or with antimicrobial peptides at 35°C for 14 h in a total volume of 200 μ l. Aliquots containing all assay reagents except cells were used as blanks. After incubation, the absorbance at 550 and 590 nm was measured using a microplate reader (Model680 Bio-Rad Laboratories, Inc., Hercules, CA) and expressed as bacterial growth. EC₅₀ values of antimicrobial activities were determined as the concentrations of peptides that were required for 50% inhibition of the maximum microbial growth (absorbance at 550 and 590 nm) observed in the absence of antimicrobial peptides. In preliminary experiments, a standard curve of each bacterial clone was obtained by performing alamarBlue assay with serially diluted bacterial suspensions, and the optimal concentrations of each bacterial species, described above, were determined for the quantifications.

Antibacterial activities against *P. gingivalis* were determined by a colony formation assay under anaerobic conditions. In brief, *P. gingivalis*, supplied by Dr Tomoko Ohshima and Professor Nobuko Maeda (Department of Oral Bacteriology, Tsurumi University, School of Dental Medicine), was cultured in Brain Heart Infusion (BHI) broth containing hemin chloride (5 μ g/ml) and vitamin K₂ (1 μ g/ml) with shaking under anaerobic condition, at 37°C for 3 to 4 days. Then, the cells were centrifuged, suspended at 5x10³ CFU/ml in BHI broth, and incubated without or with antimicrobial peptides at 37°C for 30 min. Thereafter, the cells (~500 CFU) were spread on blood agar plates and incubated under anaerobic conditions at 37°C for 6 days to allow full colony development. Antimicrobial activities of the peptides were evaluated by counting the colonies formed.

Membrane permeabilization assay. To examine the ability of antimicrobial peptides to permeabilize the outer and inner membranes of bacteria, we used *E. coli* ML-35p as a target organism (3,15,26,27). *E. coli* ML-35p was constructed by transforming *E. coli* ML-35 (i⁻, y⁻, z⁺) with pBR322 to constitutively express plasmid encoded periplasmic β -lactamase. Because ML-35p is constitutive for cytoplasmic β -galactosidase but lactose permease-deficient like its parent strain *E. coli* ML-35, intact *E. coli* ML-35p cells cannot hydrolyze β -galactosidase substrate until their cytoplasmic membranes are permeabilized by antibacterial peptides. After cells were cultured in tryptic soy broth containing 50 μ g/ml ampicillin at 37°C for 14 h, cells were washed three times with 10 mM phosphate buffer (pH 7.4) containing 150 mM NaCl, and diluted in the same buffer to 1x10⁸ CFU/ml. Outer and inner membrane permeabilization of *E. coli* ML-35p was evaluated by following the unmasked periplasmic β -lactamase and cytoplasmic β -galactosidase activities using PADAC, a




Figure 2. Antimicrobial activities of CAP11-related peptides against *E. coli* and *S. aureus*. Antibacterial activities of CAP11-related peptides (CAP11, G¹-R¹⁸, 1-18m1 and 2) were assayed with the alamarBlue assay using *E. coli* (A), methicillin-sensitive *S. aureus* (MSSA) (B), and methicillin-resistant *S. aureus* (MRSA) (C) as targets. Data are the mean \pm SD of four independent experiments.

chromogenic cephalosporin, and ONPG as substrates, respectively. The assay was performed at 37°C with shaking in a 96-well microplate containing 10^7 CFU/ml of *E. coli* ML-35p, 200 μ M PADAC or 1 mM ONPG in a total volume of 200 μ l 10 mM phosphate buffer (pH 7.4) containing 150 mM NaCl. The reactions were started by addition of antibacterial peptides or 0.01% HCl (a solvent of antibacterial peptides), and monitored for 30 min at 570 or 405 nm with a microplate reader (Model BenchmarkPlus, Bio-Rad Laboratories). Membrane permeabilization was determined by calculating the changes in the absorbance at linear portion and expressed as a percent of the enzyme activity determined with bacteria completely permeabilized by sonication.

Helical wheel prediction. The α -helical wheel structures of CAP11-derived peptides were predicted by using a Genetyx-Win computer system (Genetyx, Tokyo, Japan) and a Java applet on WWW (<http://cti.itc.virginia.edu/~cmg/Demo/wheel/wheelApp.html>).

Hydropathy indices calculated by the algorithm of Hopp and Woods, and pI values of CAP11 and its derivatives (G¹-R¹⁸, 1-18m1 and 2) were also determined by the same system.

Results

Antibacterial activities of 18-mer peptides against *E. coli* and *S. aureus*. We first examined the antibacterial activities of G¹-R¹⁸-derived 18-mer peptides using *E. coli* and MSSA as target organisms. The 18-mer peptides, as well as CAP11, dose-dependently inhibited the growth of both *E. coli* and MSSA (Fig. 2A and B). Interestingly, 1-18m2 was the most potent among the peptide derivatives at suppressing the growth of these bacteria. ED₅₀ values against *E. coli* and MSSA were 0.023 and 0.008 μ M for 1-18m2, 0.085 and 0.063 μ M for 1-18m1, 2.91 and >1 μ M for G¹-R¹⁸, and 0.202 and 0.107 μ M for CAP11, respectively.

We next assessed the antibacterial activities of G¹-R¹⁸-derived 18-mer peptides using MRSA as a target organism. Similar to the actions on MSSA, the peptide derivatives suppressed the growth of MRSA in a dose-dependent manner, and 1-18m2 was the most potent among the CAP11-derived peptides (Fig. 2C). ED₅₀ values against MRSA were 0.024 μ M for 1-18m2, 0.096 μ M for 1-18m1 and CAP11, >1 μ M for G¹-R¹⁸.

Antibacterial activities of 18-mer peptides against *P. gingivalis* and *C. albicans*. Further, we evaluated the antimicrobial actions of CAP11-derived peptides using *P. gingivalis* and *C. albicans* as target organisms. Similar to the actions on aerobic bacteria (*E. coli* and *S. aureus*), CAP11-derived peptides dose-dependently inhibited the growth of an anaerobic bacterium (*P. gingivalis*) and a fungus (*C. albicans*), and 1-18m2 was the most potent among the peptide derivatives (Fig. 3A and B). ED₅₀ values against *P. gingivalis* were 0.195 μ M for 1-18m2, 1.28 μ M for 1-18m1, >10 μ M for G¹-R¹⁸, and 6.1 μ M for CAP11. ED₅₀ values against *C. albicans* were 0.72 μ M for 1-18m2, 1.30 μ M for 1-18m1, >10 μ M for G¹-R¹⁸, and 1.92 μ M for CAP11.

Membrane-permeabilization activities of 18-mer peptides against *E. coli* ML-35p. Finally, to elucidate the mechanism for the antimicrobial actions of CAP11-derived peptides, we assessed their membrane-permeabilization activities using *E. coli* ML-35p as a target organism. Outer and inner membrane permeabilization is determined by quantifying the unmasked periplasmic β -lactamase and cytoplasmic β -galactosidase activities of *E. coli* ML-35p, respectively. The peptide derivatives dose-dependently induced the outer and inner membrane permeabilization. Consistent with the results of antimicrobial activities, 1-18m2 was the most potent among the CAP11-derived peptides at inducing the inner membrane permeabilization (ED₅₀ values, 0.16 μ M for 1-18m2, 0.51 μ M for 1-18m1 and >10 μ M for G¹-R¹⁸ and CAP11) (Fig. 4A). In contrast, the outer membrane permeabilizing activities of 1-18m2, 1 and CAP11 were almost the same (ED₅₀ values, 1.10 to 5.03 μ M) (Fig. 4B).

Discussion

For prevention of bacterial infection and their related symptoms (e.g. Gram-negative bacterial septic shock), much attention is focused on the low-molecular-weight cationic antibacterial peptides that possess potent antimicrobial activity. CAP11 has a unique homodimeric structure of 43-amino-acid peptides with a disulfide bridge (12,13). In a previous study, we revealed that the peptide dimerization is not necessary for the biological activities of CAP11. Moreover, we determined the biologically active region of CAP11, which is located at the




Figure 3. Antimicrobial activities of CAP11-related peptides against *P. gingivalis* and *C. albicans*. Antimicrobial activities of CAP11-related peptides (CAP11, G¹-R¹⁸, 1-18m1 and 2) were assayed with the colony formation and alamarBlue assays using *P. gingivalis* (A) and *C. albicans* (B), respectively, as targets. Data are the mean \pm SD of three to four independent experiments.




Figure 4. Bacterial membrane-permeabilization activities of CAP11-related peptides. *E. coli* ML-35p was incubated in the absence or presence of CAP11-related peptides (CAP11, G¹-R¹⁸, 1-18m1 and 2) with an enzyme substrate (PADAC and ONPG) for measuring periplasmic β -lactamase and cytoplasmic β -galactosidase activities, respectively. Inner (A) and outer (B) membrane permeabilization is expressed as a percent of the enzyme activity determined with bacteria completely permeabilized by sonication. Data are the mean \pm SD of four independent experiments.

N-terminus (G¹-R¹⁸) of CAP11. However, the biological activities of the short peptide (G¹-R¹⁸) were much lower than those of a full-length CAP11. Thus, in the present study, we aimed to develop the antimicrobial peptide(s) with enhanced biological activities by amino acid substitutions, using G¹-R¹⁸ as a template. Some antimicrobial peptides conform to an amphipathic α -helix structure with the hydrophobic and hydrophilic (positively charged) surfaces (5,30). Of note, structure-activity relationship (SAR) studies using different kinds of natural and synthetic model peptides revealed that the activities of amphipathic α -helical antimicrobial peptides is influenced by parameters such as charge (cationicity), hydrophobicity and amphipathicity, and that the maximum antibacterial potency is obtained when high charge (cationicity) and amphipathicity are achieved (20,21). Based on these observations, we constructed the two modified peptides, 1-18m1 and 2, with the increased hydrophobicity and hydrophilicity (positive charge) (Figs. 1 and 5).

We evaluated the antibacterial activities of the peptides against Gram-negative and -positive bacteria. The antibacterial

activities of the two peptides (1-18m1 and 2) against *E. coli* and *S. aureus* (MSSA) were markedly increased compared with those of G¹-R¹⁸; 1-18m1 has almost the same activity as CAP11, and 1-18m2 exhibited the most potent activities, which were \sim 10-fold stronger than those of CAP11. Of note, CAP11 and its modified peptides (1-18m1 and 2) also possessed the potent antibacterial activities against MRSA. These results suggest that CAP11-derived peptides (CAP11, 1-18m1 and 2) exhibit the antibacterial activities against *S. aureus* despite the methicillin-resistance.

Further, we evaluated the antimicrobial activities of CAP11-derived peptides against *P. gingivalis*, an anaerobic bacterium, and *C. albicans*, a fungus. CAP11 and its related peptides exhibited potent antimicrobial activities against these microorganisms, and 1-18m2 was the most potent. However, these microbes were relatively resistant to the CAP11-derived peptides; EC₅₀ values ($>0.195 \mu\text{M}$) against *P. gingivalis* and *C. albicans* were 20-fold higher than those ($>0.008 \mu\text{M}$) against *E. coli* and *S. aureus*. In concordance with our findings, previous studies revealed that *P. gingivalis*




Figure 5. Hydrophilicity/hydrophobicity plots of CAP11-related peptides. Hydropathy indices (+, hydrophilicity; -, hydrophobicity) of CAP11 and its related peptides (G^1 - R^{18} , 1-18m1, and 2) were calculated by the algorithm of Hopp and Woods by using a Genetyx-Win computer system, and the pI values of the peptides were also determined by the same system. Horizontal axes display the amino acid position number.

and *C. albicans* were resistant to antimicrobial peptides such as LL-37 and β -defensin 3; MIC values ($>22 \mu\text{M}$) against *P. gingivalis* and *C. albicans* were much higher than those ($>1.2 \mu\text{M}$) against *E. coli* and *S. aureus* based on a radial diffusion assay (15,28,29). *P. gingivalis* forms a biofilm, which confers the resistance to antimicrobial agents (30). Furthermore, *P. gingivalis* produces the two families of cysteine-proteases, Arg- and Lys-gingipain, which digest various peptides at arginine or lysine residue, respectively (31-33). CAP11 and its related peptides contain several cationic amino acids (i.e., Arg and Lys) in their sequences. Thus, the gingipains are likely to degrade these cationic amino acid-containing peptides during incubation, which confers the resistance on the microbe to antibacterial peptides. Bacterial membrane contains abundant negative-charged phospholipids such as phosphatidyl glycerol and cardiolipin (21,34). Therefore, the cationic antibacterial peptides possess high affinities for bacterial membrane components and kill bacteria by permeabilization and/or disruption of their membrane (17,21,34). In contrast, the mammalian cell membrane is mainly composed of uncharged phospholipids, such as phosphatidylcholine and sphingomyelin, resulting in a lower affinity of antibacterial peptides against mammalian cells. Moreover, the existence of membrane-stabilizing cholesterol protects mammalian host cells from the toxicity of antibacterial peptides. Comparable to eukaryotic cells, fungi, such as

C. albicans, have a bilayered membrane structure, which contains several sterols such as ergosterol and zymosterol. Thus, it is speculated that antimicrobial peptides have difficulty in contacting to and disrupting the fungal membrane, making *C. albicans* resistant to antimicrobial peptides.

To further elucidate the antimicrobial mechanism of CAP11-derived peptides, we investigated that membrane-permeabilization activity using *E. coli* ML-35p by measuring β -lactamase and -galactosidase activities. Except for G^1 - R^{18} , the peptides disrupted the outer membrane in a dose-dependent manner with the similar EC_{50} values (1.10 to $5.03 \mu\text{M}$). In contrast, for the inner membrane-permeabilization, 1-18m2 showed the most potent activity with the EC_{50} value of $0.16 \mu\text{M}$. Unexpectedly, CAP11 only minimally possessed inner membrane-permeabilization activity ($\sim 30\%$) even at $>10 \mu\text{M}$. These observations suggest that the potent antibacterial activities of 1-18m2 likely depend on its preferential action on the inner membrane-permeabilization.

In this study, to develop CAP11-derived antimicrobial peptides with enhanced bactericidal activities, we utilized the 18-mer peptide (G^1 - R^{18}) of CAP11 as a template, and evaluated the activities of its peptide derivatives. By replacement of K^5 , T^9 , R^{10} , R^{12} and G^{17} with five L residues, hydrophobicity of the peptide was increased and the hydrophobic sector in the helix was extended (Figs. 1 and 5; G^1 - R^{18} vs. 1-18m1). Furthermore, by replacement of G^1 and Q^{14} with K and R



respectively, hydrophilicity of the peptide was and the positively charged hydrophilic sector in the helix was expanded (1-18m1 vs. 1-18m2). Among these peptides, 1-18m2 displayed the most potent antibacterial and membrane-permeabilizing activities. Thus, the enhanced hydrophobicity and hydrophilicity (positive charge) of 1-18m2 are important for the expression of its augmented antibacterial activities. These observations suggest that the α -helical amphipathic anti-microbial peptides, with increased hydrophobicity and hydrophilicity (positive charge) (1-18m2), interact more potently with negatively charged amphipathic bacterial membrane, compared with the parent 18-mer peptide, thereby exerting augmented bactericidal activities. In contrast, the deduced pI values of CAP11-derived peptides were not essentially changed after the amino acid substitutions; 13.11 for G¹-R¹⁸, 12.81 for 1-18m1, 12.99 for 1-18m2 and 12.31 for CAP11 (Fig. 5), suggesting that antibacterial activities of CAP11 and its related peptides could not be determined simply by the basic (cationic) features of the molecules.

Cationic antimicrobial peptides target cell-surface anionic lipids (phosphatidyl glycerol and cardiolipin) that are abundant in microorganisms; the action is not receptor-based but involves a less specific interaction with microbial membrane components (21,34). The simple electrostatic interaction between cationic antimicrobial peptides and microbial membrane lipids provides selective toxicity (bacteria vs. mammalian cells) as well as a broad spectrum of antimicrobial activities. Moreover, development of microbial resistance is assumed to be low, because the target molecules (anionic lipids) are important components conserved among microorganisms, and the molecular recognition between cationic peptides and target molecules is rather lenient (3,21,34). In addition, sizes of the peptides are small, and their syntheses are relatively accessible. From these points of view, cationic antimicrobial peptides are a promising candidate for new antibiotics with therapeutic value. Previously, we revealed that CAP11 possesses not only antimicrobial activity but also LPS-neutralizing activity. Preliminarily, we evaluated the LPS-neutralizing activities of 1-18m1 and 2, based on the suppression of LPS-binding to CD14-positive RAW264.7 cells, and of LPS-induced cytokine production from these cells. Notably, these modified peptides exhibited potent LPS-neutralizing activities, and 1-18m2 was ~20-fold more potent than CAP11 (unpublished data). These observations suggest that the modified CAP11-related peptides are one of the new classes of antibiotics that can be used for treatment of microbial infections and their related symptoms (Gram-negative bacterial sepsis) in the future.

Acknowledgements

This work was supported in part by grants from Grant-in-Aid for 21st Century COE research and the Institute for Environmental and Gender-specific Medicine, Juntendo University School of Medicine.

References

- Hancock RE and Diamond G: The role of cationic antimicrobial peptides in innate host defences. *Trends Microbiol* 8: 402-410, 2000.
- Risso A: Leukocyte antimicrobial peptides: multifunctional effector molecules of innate immunity. *J Leukoc Biol* 68: 785-792, 2000.
- Gennaro R and Zanetti M: Structural features and biological activities of the cathelicidin-derived antimicrobial peptides. *Biopolymers* 55: 31-49, 2000.
- Gudmundsson GH and Agerberth B: Neutrophil antibacterial peptides, multifunctional effector molecules in the mammalian immune system. *J Immunol Methods* 232: 45-54, 1999.
- Lehrer RI and Ganz T: Cathelicidins: a family of endogenous antimicrobial peptides. *Curr Opin Hematol* 9: 18-22, 2002.
- Lehrer RI and Ganz T: Defensins of vertebrate animals. *Curr Opin Immunol* 14: 96-102, 2002.
- Lehrer RI, Lichtenstein AK and Ganz T: Defensins: antimicrobial and cytotoxic peptides of mammalian cells. *Annu Rev Immunol* 11: 105-128, 1993.
- Martin E, Ganz T and Lehrer RI: Defensins and other endogenous peptide antibiotics of vertebrates. *J Leukoc Biol* 58: 128-136, 1995.
- Zanetti M, Gennaro R and Romeo D: Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. *FEBS Lett* 374: 1-5, 1995.
- Hancock RE and Chapple DS: Peptide antibiotics. *Antimicrob Agents Chemother* 43: 1317-1323, 1999.
- Kirikae T, Hirata M, Yamasu H, Kirikae F, Tamura H, Kayama F, Nakatsuka K, Yokochi T and Nakano M: Protective effects of a human 18-kilodalton cationic antimicrobial protein (CAP18)-derived peptide against murine endotoxemia. *Infect Immun* 66: 1861-1868, 1998.
- Nagaoka I, Tsutsumi-Ishii Y, Yomogida S and Yamashita T: Isolation of cDNA encoding guinea pig neutrophil cationic antibacterial polypeptide of 11 kDa (CAP11) and evaluation of CAP11 mRNA expression during neutrophil maturation. *J Biol Chem* 272: 22742-22750, 1997.
- Yomogida S, Nagaoka I and Yamashita T: Purification of the 11- and 5-kDa antibacterial polypeptides from guinea pig neutrophils. *Arch Biochem Biophys* 328: 219-226, 1996.
- Turner J, Cho Y, Dinh NN, Waring AJ and Lehrer RI: Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. *Antimicrob Agents Chemother* 42: 2206-2214, 1998.
- Nagaoka I, Hirota S, Yomogida S, Ohwada A and Hirata M: Synergistic actions of antibacterial neutrophil defensins and cathelicidins. *Inflamm Res* 49: 73-79, 2000.
- Larrick JW, Hirata M, Zhong J and Wright SC: Anti-microbial activity of human CAP18 peptides. *Immunotechnology* 1: 65-72, 1995.
- Levy O: Antimicrobial proteins and peptides of blood: templates for novel antimicrobial agents. *Blood* 96: 2664-2672, 2000.
- Nagaoka I, Hirota S, Niyonsaba F, Hirata M, Adachi Y, Tamura H and Heumann D: Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF- α by blocking the binding of LPS to CD14⁺ cells. *J Immunol* 167: 3329-3338, 2001.
- Hancock RE and Scott MG: The role of antimicrobial peptides in animal defenses. *Proc Natl Acad Sci USA* 97: 8856-8861, 2000.
- Giangaspero A, Sandri L and Tossi A: Amphipathic α helical antimicrobial peptides. *Eur J Biochem* 268: 5589-5600, 2001.
- Tossi A, Sandri L and Giangaspero A: Amphipathic, α -helical antimicrobial peptides. *Biopolymers* 55: 4-30, 2000.
- Okuda D, Yomogida S, Tamura H and Nagaoka I: Determination of the antibacterial and lipopolysaccharide-neutralizing regions of guinea pig neutrophil cathelicidin peptide CAP11. *Antimicrob Agents Chemother* 50: 2602-2607, 2006.
- DeForge LE, Billeci KL and Kramer SM: Effect of IFN- γ on the killing of *S. aureus* in human whole blood. Assessment of bacterial viability by CFU determination and by a new method using alamarBlue. *J Immunol Methods* 245: 79-89, 2000.
- Tenover FC, Swenson JM, O'Hara CM and Stocker SA: Ability of commercial and reference antimicrobial susceptibility testing methods to detect vancomycin resistance in enterococci. *J Clin Microbiol* 33: 1524-1527, 1995.
- Yajko DM, Madej JJ, Lancaster MV, Sanders CA, Cawthon VL, Gee B, Babst A and Hadley WK: Colorimetric method for determining MICs of antimicrobial agents for *Mycobacterium tuberculosis*. *J Clin Microbiol* 33: 2324-2327, 1995.
- Lehrer RI, Barton A, Daher KA, Harwig SS, Ganz T and Selsted ME: Interaction of human defensins with *Escherichia coli*. Mechanism of bactericidal activity. *J Clin Invest* 84: 553-561, 1989.

27. Lehrer RI, Barton A and Ganz T: Concurrent assessment of inner and outer membrane permeabilization and bacteriolysis in *E. coli* by multiple-wavelength spectrophotometry. *J Immunol Methods* 108: 153-158, 1988.
28. Ciornei CD, Sigurdardottir T, Schmidtchen A and Bodelsson M: Antimicrobial and chemoattractant activity, lipopolysaccharide neutralization, cytotoxicity, and inhibition by serum of analogs of human cathelicidin LL-37. *Antimicrob Agents Chemother* 49: 2845-2850, 2005.
29. Ouhara K, Komatsuzawa H, Yamada S, Shiba H, Fujiwara T, Ohara M, Sayama K, Hashimoto K, Kurihara H and Sugai M: Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, β -defensins and LL37, produced by human epithelial cells. *J Antimicrob Chemother* 55: 888-896, 2005.
30. Mah TF and O'Toole GA: Mechanisms of biofilm resistance to antimicrobial agents. *Trends Microbiol* 9: 34-39, 2001.
31. Abe N, Kadowaki T, Okamoto K, Nakayama K, Ohishi M and Yamamoto K: Biochemical and functional properties of lysine-specific cysteine proteinase (Lys-gingipain) as a virulence factor of *Porphyromonas gingivalis* in periodontal disease. *J Biochem (Tokyo)* 123: 305-312, 1998.
32. Kadowaki T, Yoneda M, Okamoto K, Maeda K and Yamamoto K: Purification and characterization of a novel arginine-specific cysteine proteinase (argingipain) involved in the pathogenesis of periodontal disease from the culture supernatant of *Porphyromonas gingivalis*. *J Biol Chem* 269: 21371-21378, 1994.
33. Pike R, McGraw W, Potempa J and Travis J: Lysine- and arginine-specific proteinases from *Porphyromonas gingivalis*. Isolation, characterization, and evidence for the existence of complexes with hemagglutinins. *J Biol Chem* 269: 406-411, 1994.
34. Matsuzaki K: Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. *Biochim Biophys Acta* 1462: 1-10, 1999.